Cystic fibrosis–related diabetes in children: An update

Roy J. Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cystic fibrosis–related diabetes mellitus (CFRD) is the most common endocrine complication of cystic fibrosis (CF), affecting more than 50% of patients by the 4th decade of life. CFRD is often preceded by worsening pulmonary status and nutritional decline. Treatment of CFRD is associated with improvements in body weight and pulmonary function and a reduction in pulmonary exacerbations. Because of the clinical significance of CFRD, diabetes screening with an oral glucose tolerance test (OGTT) is recommended annually for all patients with CF starting at age 10 years. The OGTT detects CFRD with greater sensitivity than random glucose or hemoglobin A1c testing. The first-line treatment for CFRD is insulin. The use of other treatments such as oral medications remains under study.

Original languageEnglish (US)
Pages (from-to)e321-e326
JournalPediatric Annals
Volume45
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Diabetes Mellitus
Glucose Tolerance Test
Cystic Fibrosis
Lung
Nutritional Status
Hemoglobins
Therapeutics
Body Weight
Insulin
Glucose

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Cystic fibrosis–related diabetes in children : An update. / Kim, Roy J.

In: Pediatric Annals, Vol. 45, No. 9, 01.09.2016, p. e321-e326.

Research output: Contribution to journalArticle

Kim, Roy J. / Cystic fibrosis–related diabetes in children : An update. In: Pediatric Annals. 2016 ; Vol. 45, No. 9. pp. e321-e326.
@article{22121e74988348e487d4f2df7f2e66da,
title = "Cystic fibrosis–related diabetes in children: An update",
abstract = "Cystic fibrosis–related diabetes mellitus (CFRD) is the most common endocrine complication of cystic fibrosis (CF), affecting more than 50{\%} of patients by the 4th decade of life. CFRD is often preceded by worsening pulmonary status and nutritional decline. Treatment of CFRD is associated with improvements in body weight and pulmonary function and a reduction in pulmonary exacerbations. Because of the clinical significance of CFRD, diabetes screening with an oral glucose tolerance test (OGTT) is recommended annually for all patients with CF starting at age 10 years. The OGTT detects CFRD with greater sensitivity than random glucose or hemoglobin A1c testing. The first-line treatment for CFRD is insulin. The use of other treatments such as oral medications remains under study.",
author = "Kim, {Roy J.}",
year = "2016",
month = "9",
day = "1",
doi = "10.3928/19382359-20160815-01",
language = "English (US)",
volume = "45",
pages = "e321--e326",
journal = "Pediatric Annals",
issn = "0090-4481",
publisher = "Slack Incorporated",
number = "9",

}

TY - JOUR

T1 - Cystic fibrosis–related diabetes in children

T2 - An update

AU - Kim, Roy J.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Cystic fibrosis–related diabetes mellitus (CFRD) is the most common endocrine complication of cystic fibrosis (CF), affecting more than 50% of patients by the 4th decade of life. CFRD is often preceded by worsening pulmonary status and nutritional decline. Treatment of CFRD is associated with improvements in body weight and pulmonary function and a reduction in pulmonary exacerbations. Because of the clinical significance of CFRD, diabetes screening with an oral glucose tolerance test (OGTT) is recommended annually for all patients with CF starting at age 10 years. The OGTT detects CFRD with greater sensitivity than random glucose or hemoglobin A1c testing. The first-line treatment for CFRD is insulin. The use of other treatments such as oral medications remains under study.

AB - Cystic fibrosis–related diabetes mellitus (CFRD) is the most common endocrine complication of cystic fibrosis (CF), affecting more than 50% of patients by the 4th decade of life. CFRD is often preceded by worsening pulmonary status and nutritional decline. Treatment of CFRD is associated with improvements in body weight and pulmonary function and a reduction in pulmonary exacerbations. Because of the clinical significance of CFRD, diabetes screening with an oral glucose tolerance test (OGTT) is recommended annually for all patients with CF starting at age 10 years. The OGTT detects CFRD with greater sensitivity than random glucose or hemoglobin A1c testing. The first-line treatment for CFRD is insulin. The use of other treatments such as oral medications remains under study.

UR - http://www.scopus.com/inward/record.url?scp=84988638316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988638316&partnerID=8YFLogxK

U2 - 10.3928/19382359-20160815-01

DO - 10.3928/19382359-20160815-01

M3 - Article

C2 - 27622916

AN - SCOPUS:84988638316

VL - 45

SP - e321-e326

JO - Pediatric Annals

JF - Pediatric Annals

SN - 0090-4481

IS - 9

ER -